Eli Lilly’s momentum stems from blockbuster ... LLY’s pipeline spans promising Alzheimer’s drug donanemab, precision oncology, and AI-led antimicrobials, with OpenAI-backed supercomputing ...

Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns ...

INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture ...

Axcelis Technologies, Inc. , a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that it will showcase its innovative Puriontm platform of ion ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid ... delaying its review of the drug. Lilly said the US regulator “wants ...